Search results for "Urologia"

showing 10 items of 1005 documents

Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis

2018

ObjectiveTo investigate clinical and radiological outcomes of women with relapsing-remitting multiple sclerosis (RRMS) undergoing abortion.MethodsAn independent, multicentre retrospective study was conducted collecting data from eight Italian MS centres. We compared the preconception and postabortion annualised relapse rate (ARR) and number of Gadolinium enhancing (Gd+) lesions, by analyses of covariance. Variables associated with postabortion clinical and MRI activity were investigated using Poisson regression models; each abortion was considered as a statistical unit.ResultsFrom 1995 to 2017, we observed 188 abortions (17 elective) in 153 women with RRMS. Abortions occurred after a mean t…

AdultMalemedicine.medical_specialtyMultiple SclerosisGadoliniumNeuroimagingDiseaseRelapsing-RemittingAbortionSettore MED/26annualised relapse rateYoung Adult03 medical and health sciencessymbols.namesakeMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrencemedicineHumansPoisson regressionRetrospective StudiesInflammationPregnancy030219 obstetrics & reproductive medicinebusiness.industryObstetricsMultiple sclerosisInducedAbortionAbortion InducedRetrospective cohort studymedicine.diseaseMagnetic Resonance Imaginggadolinium enhancing lesionDiscontinuationPsychiatry and Mental healthPregnancy Maintenancemultiple sclerosisymbolsSettore MED/26 - NeurologiaFemaleSurgerypregnancyNeurology (clinical)business030217 neurology & neurosurgeryabortion; annualised relapse rate; gadolinium enhancing lesion; multiple sclerosis; pregnancyJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.

2009

Background: There are a few and conflicting results from randomised controlled trials (RCTs) pertaining to the influence of gender in response to currently used disease modifying drugs in Multiple Sclerosis (MS). Observational studies may be especially valuable for answering effectiveness questions in subgroups not studied in RCTs. Objective: To conduct a post-marketing analysis aimed to evaluate the gender effect on Interferon beta (IFN beta) treatment response in a cohort of relapsing (RR) MS patients. Methods: A cohort of 2570 IFN beta-treated RRMS was prospectively followed for Lip to 7 years in 15 Italian MS Centers. Cox proportional hazards regression models were used to assess gender…

AdultMalemedicine.medical_specialtyMultiple SclerosisPropensity scoreDiseasegender; interferon beta; multiple sclerosis; observational study; propensity scoreLower riskSeverity of Illness IndexMultiple sclerosis Interferon beta Gender Observational study Propensity scoreCohort StudiesDisability EvaluationYoung AdultSex Factorsgender multiple sclerosis treatment interferonDouble-Blind MethodInternal medicineObservational studymedicinegenderConfidence IntervalsOdds RatioProduct Surveillance PostmarketingHumansImmunologic FactorsMultiple sclerosiProportional Hazards ModelsExpanded Disability Status ScaleProportional hazards modelbusiness.industryMultiple sclerosisDrug Administration RoutesInterferon-betamedicine.diseaseInterferon betaSurgeryNeurologyItalyCohortPropensity score matchingRegression AnalysisSettore MED/26 - NeurologiaObservational studyFemaleNeurology (clinical)business
researchProduct

Cigarette Smoking Status at Diagnosis and Recurrence in Intermediate-risk Nonemuscle-invasive Bladder Carcinoma

2013

Objective To study the effect of smoking status at diagnosis on recurrence in intermediate-risk non–muscle-invasive bladder carcinoma treated by transurethral resection (TUR) of the bladder and early intravesical chemotherapy. Methods Tumor characteristics and smoking status were recorded in 395 patients entered in a randomized multicenter trial comparing 2 different schedules of early intravesical chemotherapy. All patients received intravesical epirubicin (80 mg/50 mL) within 6 hours after TUR, followed by 5 more weekly instillations with (arm B) or without (arm A) monthly instillations for 1 year. Smoking habit was investigated at diagnosis through a structured questionnaire. Multivariat…

AdultMalemedicine.medical_specialtyMultivariate analysisTime Factorsintravesical chemotherapy non-muscle invasive bladder cancerUrologymedicine.medical_treatmentcigarette smokingKaplan-Meier EstimateCystectomyGastroenterologyDisease-Free SurvivalSettore MED/24 - UrologiaCystectomyCigarette smokingRisk FactorsMulticenter trialInternal medicinemedicineCarcinomaHumansAgedEpirubicinProportional Hazards ModelsAged 80 and overAntibiotics AntineoplasticProportional hazards modelbusiness.industryCarcinomaSmokingMiddle AgedFormer Smokermedicine.diseaseintermediate-risk tumorrecurrence.Combined Modality TherapySurgeryUrinary Bladder NeoplasmsMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessEpirubicinmedicine.drug
researchProduct

Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospina…

2015

The etiology of multiple sclerosis (MS) is still largely unknown and it has been proposed that an impaired venous drainage from the central nervous system, defined as chronic cerebrospinal venous insufficiency (CCSVI), may play a role in this. We investigated the prevalence of extracranial venous drainage pattern alterations in a cohort of MS patients based on the 2011 revised diagnostic criteria for CCSVI. Thirty-nine MS patients and 18 healthy subjects underwent blinded extra-cranial venous echo-color Doppler sonography to reveal the presence of CCSVI. There was no statistically significant difference between MS patients and healthy controls regarding CCSVI prevalence (p value = 0.53). Th…

AdultMalemedicine.medical_specialtyNeurologyChronic cerebrospinal venous insufficiencyUltrasonography Doppler TranscranialTranscranial030204 cardiovascular system & hematologyPathogenesisMultiple sclerosis03 medical and health sciences0302 clinical medicineEcho-color Doppler sonographyInternal medicineCerebral venous outflow; Chronic cerebrospinal venous insufficiency; Echo-color Doppler sonography; Multiple sclerosis; Neurology (clinical); NeurologymedicinePrevalenceHumansUltrasonographybusiness.industryMultiple sclerosisDopplerVenous drainageMiddle Agedmedicine.diseaseSurgerySettore MED/26 - NEUROLOGIADoppler sonographyChronic cerebrospinal venous insufficiencyVenous InsufficiencyNeurologyCase-Control StudiesCohortEtiologyCardiologyFemaleNeurology (clinical)Cerebral venous outflowbusiness030217 neurology & neurosurgery
researchProduct

Natalizumab: a country-based surveillance program

2008

Natalizumab is a humanized monoclonal antibody with a selective adhesion-molecule inhibitor effect, and a demonstrated efficacy in decreasing the frequency of relapses and progression of disability in relapsing-remitting multiple sclerosis (RR MS). After the approval of FDA and EMEA in MS cases unresponsive to immunomodulating therapy or in severe MS patients also not previously treated with interferons, and considering the concern on the possible side effects, an accurate program of surveillance was organized in our country by a combined effort of AIFA, Cineca, Department of Pharmacology of University of Bologna, and a group of neurologists appointed by the National Society of Neurology (S…

AdultMalemedicine.medical_specialtyNeurologyDatabases FactualDrug-Related Side Effects and Adverse ReactionsNational Health ProgramsDrug ResistanceDermatologyDiseaseAntibodies Monoclonal HumanizedNatalizumabInternal medicineOutcome Assessment Health CareMultiple SclerosiPharmacovigilanceProduct Surveillance PostmarketingmedicineAdverse Drug Reaction Reporting SystemsHumansImmunologic FactorsMULTIPLE SCLEROSISNATALIZUMABClinical Trials as Topicbusiness.industryMultiple sclerosisAntibodies MonoclonalMean ageGeneral Medicinemedicine.diseasePsychiatry and Mental healthItalyREGISTRYPHARMACOVIGILANCEPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurosurgerybusinessPreviously treatedFollow-Up Studiesmedicine.drug
researchProduct

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct

Detection of possible factors favouring the evolution of migraine without aura into chronic migraine

2012

In a minority of cases, the natural history of migraine without aura (MO) is characterised over time by its evolution into a form of chronic migraine (CM). In order to detect the possible factors predicting this negative evolution of MO, we searched in our Headache Centre files for all clinical records that met the following criteria: (a) first visit between 1976 and 1998; (b) diagnosis of MO or of common migraine at the first observation, with or without association with other primary headache types; (c) <15 days per month of migraine at the first observation; and (d) at least one follow-up visit at least 10 years after the first visit. The patients thus identified were then divided into t…

AdultMalemedicine.medical_specialtyNeurologyTime FactorsAuraMigraine DisordersDermatologyYoung AdultChronic MigraineMigraine Migraine without aura Chronic migraine Chronic daily headache Chronic headacheInternal medicinemedicineHumansYoung adultDepression (differential diagnoses)business.industryDepressionGeneral MedicineMiddle Agedmedicine.diseaseComorbidityNatural historyPsychiatry and Mental healthMigraineChronic DiseaseHypertensionPhysical therapyDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)business
researchProduct

Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine

2020

Abstract Background Quarantine was the measure taken by governments to control the rapid spread of COVID-19. This restriction resulted in a sudden change in people’s lifestyle, leading to an increase in sedentary behavior and a related decrease in the practice of physical activity (PA). However, in neuromuscular diseases patients need to perform regular PA to counteract the negative consequences of the disease. Hence, the aim of this study was to estimate the levels of PA, measured as energy expenditure (MET–minute/week), among patients with neuromuscular disease (NMD) before and during the last week of quarantine. Methods A total of 268 Italian subjects, living in Sicily, completed an adap…

AdultMalemedicine.medical_specialtyNeuromuscular diseaseCoronavirus disease 2019 (COVID-19)Physical activityCoronavirus pandemic COVID-19 Lockdown NeuromuscularPhysical activity QuarantineDiseaselaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineSurveys and QuestionnairesPandemicQuarantineLockdownmedicineHumansIn patient030212 general & internal medicineExerciseSicilyAgedCoronavirus pandemicSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportiveOriginal Communicationbusiness.industryPhysical activitySARS-CoV-2COVID-19Neuromuscular DiseasesMiddle Agedmedicine.diseaseCross-Sectional StudiesNeurologyEnergy expenditureNeuromuscularQuarantineQuality of LifeSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Optokinetic stimulation affects temporal estimation in healthy humans

2007

The representation of time and space are closely linked in the cognitive system. Optokinetic stimulation modulates spatial attention in healthy subjects and patients with spatial neglect. In order to evaluate whether optokinetic stimulation could influence time perception, a group of healthy subjects performed "time-comparison" tasks of sub- and supra-second intervals before and after leftward or rightward optokinetic stimulation. Subjective time perception was biased by the direction of optokinetic stimulation. Rightward optokinetic stimulation induced an overestimation of time perception compared with baseline and leftward optokinetic stimulation. These results indicate a directional bias…

AdultMalemedicine.medical_specialtyOptokineticgenetic structuresPhotic StimulationCognitive Neurosciencemedia_common.quotation_subjectSpatial abilitySpaceExperimental and Cognitive PsychologyStimulationNystagmusAudiologyAnalysis of Variance; Perceptual Distortion; Humans; Time Perception; Psychophysics; Photic Stimulation; Adult; Cues; Space Perception; Nystagmus Optokinetic; Attention; Female; Functional Laterality; MaleFunctional LateralityTimeNystagmusArts and Humanities (miscellaneous)Optokinetic stimulation; Perception; Space; Time; Adult; Analysis of Variance; Attention; Cues; Female; Functional Laterality; Humans; Male; Nystagmus Optokinetic; Psychophysics; Perceptual Distortion; Photic Stimulation; Space Perception; Time Perception; Cognitive Neuroscience; Experimental and Cognitive Psychology; Neuropsychology and Physiological PsychologyPerceptionDevelopmental and Educational PsychologymedicinePsychophysicsPsychophysicsHumansAttentionNystagmus Optokineticmedia_commonAnalysis of VariancePerceptual DistortionSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitionSpace TimePerception Optokinetic stimulationTime perceptionNeuropsychology and Physiological PsychologySpace PerceptionTime PerceptionPerceptionFemaleSettore MED/26 - Neurologiamedicine.symptomCuesOptokinetic stimulationPsychologyPhotic StimulationCognitive psychology
researchProduct

Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.

2008

Myocardial (123)Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated MIBG uptake in 14 patients with PD associated with mutations in different genes (Parkin, DJ-1, PINK], and leucine-rich repeat kinase 2 -LRRK2), in 15 patients with idiopathic PD, and 10 control subjects. The myocardial MIGB uptake was preserved in 3 of the 4 Parkin-associated Parkinsonisms, in I of the 2 patients with DJ-1 mutations, in 1 of the 2 brothers with PINK] mutations, in 3 of the 6 unrelated patient…

AdultMalemedicine.medical_specialtyParkinson's diseaseGenotypeUbiquitin-Protein LigasesDNA Mutational AnalysisProtein Deglycase DJ-1PINK1Gene mutationProtein Serine-Threonine Kinasesmedicine.disease_causeLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Severity of Illness IndexParkinCentral nervous system diseaseDiagnosis DifferentialDegenerative diseaseParkinsonian DisordersInternal medicineSurveys and QuestionnairesmedicineHumansPoint MutationPromoter Regions GeneticGenetic PD Myocardial scintigraphyOncogene ProteinsTomography Emission-Computed Single-PhotonMutationMovement Disordersbusiness.industryMyocardiumIntracellular Signaling Peptides and ProteinsParkinson DiseaseGalvanic Skin ResponseMiddle Agedmedicine.diseaseLRRK2nervous system diseases3-IodobenzylguanidineEndocrinologyNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)RadiopharmaceuticalsbusinessProtein KinasesMovement disorders : official journal of the Movement Disorder Society
researchProduct